Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Cyramza® (ramucirumab): Administration

Ramucirumab should be diluted with sterile sodium chloride and administered using a protein sparing 0.22 micron filter as an infusion over 60 minutes.

Calculate and Prepare Ramucirumab for Administration

Prepare the infusion solution using aseptic technique to ensure the sterility of the prepared solution.1

Each vial of ramucirumab is intended for single use only.1

1. Inspect the contents of the vials for particulate matter and discoloration prior to dilution. If particulate matter or discolorations are identified, discard the vial

2. Calculate the dose and the required volume of ramucirumab needed to prepare the infusion solution.

  • Vials contain either 100 mg or 500 mg as a 10-mg/mL solution of ramucirumab.

3. Dilute ramucirumab as required to achieve a final volume of 250 mL. Only use sterile sodium chloride (0.9%) solution for injection as a diluent.

  • In case of prefilled IV infusion container usage: based on the calculated volume of ramucirumab, remove the corresponding volume of sterile sodium chloride (0.9%) solution for injection from the prefilled 250-mL IV container. Aseptically transfer the calculated volume of ramucirumab to the IV container. The final total volume in the container should be 250 mL.

  • In case of empty IV infusion container usage: aseptically transfer the calculated volume of ramucirumab into an empty IV container. Add a sufficient quantity of sterile sodium chloride (0.9%) solution for injection to the container to make the total volume 250 mL.

4. The container should be gently inverted to ensure adequate mixing.

  • Do not freeze or shake the infusion solution.

  • Do not dilute with other solutions or co-infuse with other electrolytes or medication.

5. Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is identified, discard the infusion solution.

6. Discard any unused portion of ramucirumab left in a vial, as the product contains no preservatives.1,2

Administration of Ramucirumab

Administer ramucirumab as an IV infusion only. Do not administer ramucirumab as an IV push or bolus.1

Administer diluted ramucirumab infusion via infusion pump. A separate infusion line with a protein sparing 0.22 micron filter must be used for the infusion and the line must be flushed with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.1


1. Cyramza [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.


IV = intravenous

Date of Last Review: August 12, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request